Investing

Genmab : GMAB

GMAB

Stock Data

$26.45

$0.07 (0.26%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Based in Copenhagen, Denmark, Genmab is a biotechnology firm focused on creating antibody therapeutics for cancer and other serious diseases. It is known for DARZALEX, a treatment for multiple myeloma, among other innovative drugs targeting various cancers and conditions like thyroid eye disease and NSCLC. With a robust pipeline that includes treatments for blood cancers, solid tumors, and diseases like celiac and haemophilia A, Genmab collaborates with industry leaders like Seagen Inc., argenx, and AbbVie to advance medical research and treatment options.

All Genmab Articles

2 Articles

Lee Jackson | Mar 27, 2026 at 8:04 AM EDT

Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More

Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before,…

Lee Jackson | Mar 2, 2026 at 7:56 AM EST

Here Are Monday’s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More

Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the…